Anti-HRV-A16 VPg di-uridylylated antibody (anti–VPg-pU(pU))

  • Description

  • Application Data

Description

Anti-HRVA16 VPg di-uridylylated antibody (anti–VPg-pU(pU)) raised against the N-terminal of the VPg peptide in the di-uridylylated form. VPg is crucial for Human rhinovirus (HRV) polymerisation.

See full description

Application Data

Catalogue number crb2005637
Antibody Anti-HRV-A16 VPg di-uridylylated antibody (anti–VPg-pU(pU))
Antigen Peptide KLH conjugated synthetic peptide crb1200844
Aliases VPg
Cross-Reactivity human rhinovirus (HRV)
Target Protein Species human rhinovirus (HRV)
Host Species Anti-Rabbit
Antibody Type Polyclonal
Concentration 0.5 mg/ml (R1G) 0.2 mg/ml (R2G)
Validation ELISA (1:1000)
Target HRVA16 di-uridylated
Storage Stabilisers The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles.
Disease Area Asthma, COPD
Specificity Protein
Post-translational Modification Uridylation
Storage The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles.
Citations

Gingras R, Mekhssian K, Fenwick C, White PW, Thibeault D. (2104). Human rhinovirus VPg uridylylation AlphaScreen for high-throughput screening. J Biomol Screen. Feb;19(2):259-69. PMID: 23813021.

Material Safety Data Sheet (MSDS)

Human rhinoviruses (HRV) are the leading cause of the common cold, asthma, and chronic obstructive pulmonary disease exacerbations. This has led to the search for therapies that inhibit the HRV-induced inflammatory response or prevent viral infectivity. There is significant genetic diversity in the HRV family hence a lack of natural immunity, which also hampers the development of vaccines; HRV genetic diversity also is the reason there are no available broad-spectrum antivirals with direct action on HRV. A putative strategy is the identification of rhinovirus replication inhibitors targeting the polymerase activity. An initial step in HRV replication is the conjugation of viral peptide VPg uridine nucleotides to substrates, which serve as the primer for polymerisation. An antibody was raised against virus HRV-A16 peptide VPg N-terminal (GPYSGEPKPK) in the di-uridylylated form. The HRVA16 di-uridylylated antibody was crucial. It has been possible to reconstitute the uridylylation reaction to allow high-throughput screening and use the HRV-A16 VPg di-uridylylated antibody in the assay to identify novel inhibitors of human rhinovirus (HRV) VPg uridylylation with potential uses in the future as clinical antiviral drugs.

Anti-HRV-A16 VPg di-uridylylated antibody (anti–VPg-pU(pU))

Cat No.Pack SizePriceQty.
20µg£110.00
100µg£220.00
20µg£110.00
100µg£220.00
Bulk Quote